Goldman Sachs Group Inc Viking Therapeutics, Inc. Call Options Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$47.39 - $80.2 $6.08 Million - $10.3 Million
128,300 New
128,300 $6.8 Million
Q1 2023

May 14, 2024
BUY
$8.08 - $17.33 $1.59 Million - $3.4 Million
196,200 New
196,200 $3.27 Million
Q1 2023

May 11, 2023
BUY
$8.08 - $17.33 $1.59 Million - $3.4 Million
196,200 New
196,200 $3.27 Million

Others Institutions Holding VKTX

# of Institutions
474
Shares Held
66.2M
Call Options Held
5.72M
Put Options Held
3.39M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.1B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email